Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
JAMA Dermatol. 2019 Jul 1;155(7):803-811. doi: 10.1001/jamadermatol.2019.0267.
Merkel cell carcinoma (MCC) carries the highest mortality rate among cutaneous cancers and is rapidly rising in incidence. Identification of prognostic indicators may help guide patient counseling and treatment planning. Lymph node ratio (LNR), the ratio of positive lymph nodes to the total number of examined lymph nodes, is an established prognostic indicator in other cancers.
The primary objective was to evaluate the association between LNR and patient survival after surgery for node-positive MCC. The secondary objective was to evaluate whether the survival rates associated with adjuvant therapies vary by patient LNR status.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of patients with node-positive MCC treated with surgery and lymphadenectomy. We queried the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) registry for patient records. Data originated from 2004 through 2017 for the NCDB and from 1973 through 2016 for the SEER registry. The SEER registry comprises a population-based US cohort while cases from the NCDB include all reportable cases from Commission on Cancer-accredited facilities and represents approximately 70% of all newly diagnosed cancers in the United States. All data analysis took place between August 1, 2018, and February 11, 2019.
The ratio of positive lymph nodes to the total number of examined lymph nodes, LNR, was stratified into quartiles.
Overall survival (NCDB) and disease-specific survival (SEER).
We identified 736 eligible cases in the NCDB and 538 eligible cases in the SEER registry. Among these 1274 patients, the mean (SD) age was 71.1 (11.5) years, and 401 (31.5%) were women. After controlling for clinical and tumor factors including AJCC N staging, patient LNR of 0.07 to 0.31 (hazard ratio [HR], 1.37; 95% CI, 1.03-1.81) and greater than 0.31 (HR, 2.84; 95% CI, 2.10-3.86) was associated with significantly worse survival than an LNR less than 0.07. Univariate supplementary analysis performed in the SEER data set revealed a similar association of LNR with disease-specific survival. For patients with an LNR greater than 0.31, treatment with surgery and adjuvant chemoradiation therapy was associated with improved survival compared with surgery and adjuvant radiation therapy alone (HR, 0.61; 95% CI, 0.38-0.97), while this was not found for patients with an LNR of 0.31 or lower (HR, 0.93; 95% CI, 0.65-1.33).
For lymph node-positive MCC, LNR offers a potentially prognostic metric alongside traditional TNM staging that may be useful for both patient counseling and treatment planning after surgery.
默克尔细胞癌 (MCC) 在皮肤癌中死亡率最高,且发病率迅速上升。识别预后指标可能有助于指导患者咨询和治疗计划。淋巴结比率 (LNR),即阳性淋巴结与检查淋巴结总数的比值,是其他癌症中已确立的预后指标。
本研究的主要目的是评估淋巴结阳性 MCC 患者手术后 LNR 与患者生存之间的关系。次要目的是评估与辅助治疗相关的生存率是否因患者 LNR 状态而异。
设计、地点和参与者:对接受手术和淋巴结切除术治疗的淋巴结阳性 MCC 患者进行回顾性队列研究。我们查询了国家癌症数据库 (NCDB) 和监测、流行病学和最终结果 (SEER) 登记处以获取患者记录。数据源自 2004 年至 2017 年的 NCDB 和 1973 年至 2016 年的 SEER 登记处。SEER 登记处包含了一个基于人群的美国队列,而 NCDB 的病例包括了癌症委员会认可机构报告的所有病例,约占美国所有新诊断癌症的 70%。所有数据分析均于 2018 年 8 月 1 日至 2019 年 2 月 11 日进行。
阳性淋巴结与检查淋巴结总数的比值,LNR,分为四分位。
总生存率(NCDB)和疾病特异性生存率(SEER)。
我们在 NCDB 中确定了 736 例符合条件的病例,在 SEER 登记处确定了 538 例符合条件的病例。在这 1274 名患者中,平均(SD)年龄为 71.1(11.5)岁,401 名(31.5%)为女性。在控制了包括 AJCC N 分期在内的临床和肿瘤因素后,LNR 为 0.07 至 0.31(风险比 [HR],1.37;95%CI,1.03-1.81)和大于 0.31(HR,2.84;95%CI,2.10-3.86)的患者生存明显较差。在 SEER 数据集进行的单变量补充分析中,LNR 与疾病特异性生存率也存在类似的关联。对于 LNR 大于 0.31 的患者,与单独接受手术和辅助放疗相比,接受手术和辅助放化疗治疗可改善生存(HR,0.61;95%CI,0.38-0.97),而对于 LNR 为 0.31 或更低的患者,这种关联并不存在(HR,0.93;95%CI,0.65-1.33)。
对于淋巴结阳性 MCC,LNR 提供了一种潜在的预后指标,与传统的 TNM 分期一起,可能对手术后的患者咨询和治疗计划都有用。